OncoMatch/Clinical Trials/NCT07652736
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Is NCT07652736 recruiting? Yes, currently enrolling (Jul 2026). Studying Tislelizumab for advanced non-small cell lung cancer.
Treatment: Tislelizumab — The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Tislelizumab
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07652736 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify